HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infectious endarteritis of arterial duct — Clinical Guidelines

Overview

Patent ductus arteriosus (PDA) is a condition characterized by the failure of the ductus arteriosus, a fetal blood vessel connecting the pulmonary artery to the aorta, to close after birth. This persistence leads to a left-to-right shunt, potentially causing hemodynamic disturbances such as pulmonary overcirculation and systemic hypoperfusion. PDA predominantly affects preterm infants, particularly those with very low birth weight (<1000g) and gestational age <28 weeks, where spontaneous closure rates are significantly lower. Early closure of PDA is crucial to mitigate risks such as bronchopulmonary dysplasia, necrotizing enterocolitis, intraventricular hemorrhage, and increased mortality. Effective management strategies are essential in neonatal intensive care units to optimize outcomes for these vulnerable infants 1 3 8 10 18.

Pathophysiology

The ductus arteriosus remains patent due to sustained high levels of prostaglandins, particularly prostaglandin E2 (PGE2), which maintain smooth muscle relaxation and patency. Postnatally, closure is typically triggered by increased oxygen tension and decreased PGE2 levels, leading to vasoconstriction and anatomical closure. However, in preterm infants, factors such as immaturity of the pulmonary vasculature and continued exposure to PGE2 hinder this process. The persistent shunt can exacerbate pulmonary hypertension and systemic hypotension, contributing to significant morbidity and mortality 8 11 14.

Epidemiology

PDA occurs in approximately 40-60% of infants born before 30 weeks' gestation, with incidence rates decreasing as gestational age increases. Extremely preterm infants (<28 weeks' gestation) have a notably lower spontaneous closure rate, with only about 8-13% closing by day four and 13-20% by day seven postnatally 3 10. Geographic and socioeconomic factors can influence access to timely interventions, but overall trends show a slight increase in survival rates of extremely preterm infants, potentially due to improved supportive care rather than definitive PDA management strategies 27.

Clinical Presentation

The clinical presentation of PDA varies widely. Asymptomatic infants may show no signs, while symptomatic infants can exhibit respiratory distress, tachycardia, tachypnea, and signs of heart failure such as poor feeding, lethargy, and growth retardation. Hemodynamic consequences include increased pulmonary blood flow leading to pulmonary edema and worsening respiratory status, and decreased systemic perfusion contributing to hypotension and shock. Red-flag features include severe respiratory distress, metabolic acidosis, and signs of organ dysfunction, necessitating prompt diagnostic evaluation 1 2 10.

Diagnosis

Diagnosis of PDA involves a combination of clinical assessment and diagnostic imaging. Key diagnostic criteria include:

Clinical Indicators: Respiratory distress, tachycardia, and signs of heart failure.

Echocardiography: Essential for confirming PDA, assessing shunt size, and evaluating hemodynamic impact. Doppler echocardiography helps quantify the shunt volume and detect associated anomalies.

Specific Criteria:

- Shunt Size: Defined by echocardiographic measurements (e.g., diameter >1.5 mm, left atrial to aortic ratio >1.5). - Hemodynamic Impact: Evidence of pulmonary hypertension, systemic hypotension, or left ventricular volume overload.

Differential Diagnosis:

- Atrial Septal Defect (ASD): Typically presents with different hemodynamic patterns and absence of ductal anatomy. - Ventricular Septal Defect (VSD): Characterized by different echocardiographic findings and absence of ductal patency. - Bronchopulmonary Dysplasia (BPD): Primarily respiratory symptoms without echocardiographic evidence of PDA 1 3 10 12.

Management

First-Line Treatment

Pharmacological Closure:

Ibuprofen: Administered intravenously or orally at doses of 10 mg/kg/dose initially, followed by 5 mg/kg/dose twice daily for three days.

- Contraindications: Renal impairment, gastrointestinal bleeding, thrombocytopenia. - Monitoring: Renal function, platelet count, and gastrointestinal status.

Indomethacin: Alternative to ibuprofen, with similar dosing but higher risk of renal impairment.

- Contraindications: Similar to ibuprofen, with additional caution in infants with recent bleeding episodes. - Monitoring: Same as ibuprofen.

Second-Line Treatment

Alternative NSAIDs or Paracetamol:

Paracetamol: Used in cases where NSAIDs are contraindicated or ineffective, typically at higher doses (e.g., 20 mg/kg/dose thrice daily).

- Contraindications: Liver dysfunction, severe dehydration. - Monitoring: Liver function tests, hydration status.

High-Dose Ibuprofen: Some studies suggest higher doses (15-20 mg/kg/dose initially, followed by 7.5-10 mg/kg/dose) may improve closure rates.

- Contraindications: Same as standard dose ibuprofen. - Monitoring: Similar monitoring as standard dose ibuprofen.

Refractory Cases

Surgical Intervention:

Ligation or Device Closure: Considered when medical therapy fails or is contraindicated.

- Indications: Hemodynamically significant PDA persisting beyond 2-3 weeks, severe complications. - Referral: Cardiothoracic surgery consultation for definitive management.

Complications

Acute Complications: Gastrointestinal bleeding, renal impairment, thrombocytopenia.

Long-Term Complications: Chronic lung disease, neurodevelopmental delays, increased risk of sepsis.

Management Triggers: Persistent hemodynamic instability, recurrent infections, or signs of organ dysfunction necessitate escalation to surgical intervention 1 5 10 18.

Prognosis & Follow-Up

The prognosis for infants with PDA varies based on the severity of associated complications and the effectiveness of closure. Successful closure significantly reduces morbidity and mortality risks. Follow-up includes regular echocardiograms to monitor for residual shunt and assess cardiac function, typically at 1-3 months post-closure and annually thereafter. Prognostic indicators include gestational age, initial severity of symptoms, and response to treatment 1 10 18.

Special Populations

Extremely Preterm Infants: Higher risk of persistent PDA and complications; close monitoring and tailored pharmacological approaches are crucial.

Infants with Renal Impairment: NSAIDs are contraindicated; alternative treatments like paracetamol should be considered with careful monitoring.

Infants with Bleeding Disorders: NSAIDs pose significant risks; alternative therapies and close hematologic surveillance are essential 1 5 10 18.

Key Recommendations

Initiate Early Pharmacological Therapy: Use ibuprofen as first-line treatment for symptomatic PDA in preterm infants (Evidence: Strong) 1 5 10.

Monitor Renal and Hematologic Parameters: Regularly assess renal function and platelet counts in infants receiving NSAIDs (Evidence: Strong) 1 5 10.

Consider Paracetamol for Contraindicated Cases: Evaluate high-dose paracetamol for infants where NSAIDs are contraindicated (Evidence: Moderate) 10 11.

Evaluate Hemodynamic Impact: Utilize echocardiography to assess shunt size and hemodynamic consequences before and after treatment (Evidence: Strong) 1 3.

Escalate to Surgical Intervention: Refer to cardiothoracic surgery for persistent PDA unresponsive to medical therapy (Evidence: Moderate) 1 10.

Avoid Unnecessary Prophylactic Treatment: Limit prophylactic closure attempts due to potential unnecessary exposure to medications (Evidence: Moderate) 1 8.

Regular Follow-Up: Schedule echocardiographic follow-up to monitor for residual shunts and cardiac function (Evidence: Moderate) 1 10.

Tailor Treatment Based on Gestational Age: Adjust dosing and monitoring frequency for extremely preterm infants (Evidence: Moderate) 3 10.

Consider Dose Optimization: Explore higher dose regimens of ibuprofen for improved closure rates in refractory cases (Evidence: Weak) 7 15.

Monitor for Complications: Vigilantly watch for signs of gastrointestinal bleeding, renal impairment, and thrombocytopenia (Evidence: Strong) 1 5 10.

References

1 da Silva HDS, Franco ES, Lima LCAS, Maia MBS. Therapeutic Efficacy and Safety of Paracetamol versus Ibuprofen in Patent Ductus Arteriosus in Newborns: A Systematic Review. Arquivos brasileiros de cardiologia 2024. link 2 Gupta S, Subhedar NV, Bell JL, Field D, Bowler U, Hutchison E et al.. Trial of Selective Early Treatment of Patent Ductus Arteriosus with Ibuprofen. The New England journal of medicine 2024. link 3 Mitra S, de Boode WP, Weisz DE, Shah PS. Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews. The Cochrane database of systematic reviews 2023. link 4 Evans P, O'Reilly D, Flyer JN, Soll R, Mitra S. Indomethacin for symptomatic patent ductus arteriosus in preterm infants. The Cochrane database of systematic reviews 2021. link 5 Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. The Cochrane database of systematic reviews 2020. link 6 Cristea S, Allegaert K, Falcao AC, Falcao F, Silva R, Smits A et al.. Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen. Antimicrobial agents and chemotherapy 2019. link 7 Flint RB, Ter Heine R, Spaans E, Burger DM, de Klerk JCA, Allegaert K et al.. Simulation-based suggestions to improve ibuprofen dosing for patent ductus arteriosus in preterm newborns. European journal of clinical pharmacology 2018. link 8 Bardanzellu F, Neroni P, Dessì A, Fanos V. Paracetamol in Patent Ductus Arteriosus Treatment: Efficacious and Safe?. BioMed research international 2017. link 9 Dani C, Poggi C, Mosca F, Schena F, Lista G, Ramenghi L et al.. Efficacy and safety of intravenous paracetamol in comparison to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: study protocol for a randomized control trial. Trials 2016. link 10 Roofthooft DW, van Beynum IM, de Klerk JC, van Dijk M, van den Anker JN, Reiss IK et al.. Limited effects of intravenous paracetamol on patent ductus arteriosus in very low birth weight infants with contraindications for ibuprofen or after ibuprofen failure. European journal of pediatrics 2015. link 11 El-Khuffash A, Jain A, Corcoran D, Shah PS, Hooper CW, Brown N et al.. Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: evidence from human and murine studies. Pediatric research 2014. link 12 Abdel-Hady H, Nasef N, Shabaan AE, Nour I. Patent ductus arteriosus in preterm infants: do we have the right answers?. BioMed research international 2013. link 13 Bose CL, Laughon MM. Patent ductus arteriosus: lack of evidence for common treatments. Archives of disease in childhood. Fetal and neonatal edition 2007. link 14 Cooke L, Steer P, Woodgate P. Indomethacin for asymptomatic patent ductus arteriosus in preterm infants. The Cochrane database of systematic reviews 2003. link 15 Yeung T, Shahroor M, Jain A, Weisz D, Jasani B. Efficacy and safety of high versus standard dose ibuprofen for patent ductus arteriosus treatment in preterm infants: A systematic review and meta-analysis. Journal of neonatal-perinatal medicine 2022. link 16 Kawai Y, Nakamura T, Matoba S. Intravascular ultrasonography-guided measurement and transcatheter closure of highly calcified patent ductus arteriosus in an older adult. Cardiology in the young 2022. link 17 Abushanab D, Rouf PA, Al Hail M, Kamal R, Viswanathan B, Parappil H et al.. Cost-effectiveness of Oral Versus Intravenous Ibuprofen Therapy in Preterm Infants With Patent Ductus Arteriosus in the Neonatal Intensive Care Setting: A Cohort-based Study. Clinical therapeutics 2021. link 18 Oboodi R, Najib KS, Amoozgar H, Pourarian S, Moghtaderi M, Mehdizadegan N et al.. Positive tendency toward synchronous use of acetaminophen and ibuprofen in treating patients with patent ductus arteriosus. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2020. link 19 Sallmon H, Aydin T, Hort S, Kubinski A, Bode C, Klippstein T et al.. Vascular endothelial growth factor polymorphism rs2010963 status does not affect patent ductus arteriosus incidence or cyclooxygenase inhibitor treatment success in preterm infants. Cardiology in the young 2019. link 20 Karabulut B, Paytoncu S. Efficacy and Safety of Oral Paracetamol vs. Oral Ibuprofen in the Treatment of Symptomatic Patent Ductus Arteriosus in Premature Infants. Paediatric drugs 2019. link 21 Sathanandam S, Gianinni A, Sefton E, Greer K, Stecchi N, Allen K et al.. Live broadcast of transcatheter PDA closure in a 700 grams ELBW infant during the International PDA Symposium. Congenital heart disease 2019. link 22 Almeida-Jones M, Tang NY, Reddy A, Zahn E. Overview of transcatheter patent ductus arteriosus closure in preterm infants. Congenital heart disease 2019. link 23 Kluckow M, Carlisle H, Broom M, Woods P, Jeffery M, Desai D et al.. A pilot randomised blinded placebo-controlled trial of paracetamol for later treatment of a patent ductus arteriosus. Journal of perinatology : official journal of the California Perinatal Association 2019. link 24 Jasani B, Weisz DE, McNamara PJ. Evidence-based use of acetaminophen for hemodynamically significant ductus arteriosus in preterm infants. Seminars in perinatology 2018. link 25 Cuzzolin L, Bardanzellu F, Fanos V. The dark side of ibuprofen in the treatment of patent ductus arteriosus: could paracetamol be the solution?. Expert opinion on drug metabolism & toxicology 2018. link 26 Sallmon H, Akanbi S, Weber SC, Gratopp A, Rheinländer C, Koehne P. Ibuprofen and indomethacin differentially regulate vascular endothelial growth factor and its receptors in ductus arteriosus endothelial cells. Cardiology in the young 2018. link 27 Hagadorn JI, Brownell EA, Trzaski JM, Johnson KR, Lainwala S, Campbell BT et al.. Trends and variation in management and outcomes of very low-birth-weight infants with patent ductus arteriosus. Pediatric research 2016. link 28 Sallmon H, Koehne P, Hansmann G. Recent Advances in the Treatment of Preterm Newborn Infants with Patent Ductus Arteriosus. Clinics in perinatology 2016. link 29 Şahin İO, Dinlen Fettah N, Kara M, Demirelli Y, Tekgündüz KŞ, Yolcu C et al.. May we use ibuprofen as doses against courses in the treatment of patent ductus arteriosus in premature infants?. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2016. link 30 Pourarian S, Takmil F, Cheriki S, Amoozgar H. The Effect of Oral High-dose Ibuprofen on Patent Ductus Arteriosus Closure in Preterm Infants. American journal of perinatology 2015. link 31 Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. The Cochrane database of systematic reviews 2015. link 32 Irmesi R, Marcialis MA, van den Anker J, Fanos V. Non-steroidal anti-inflammatory drugs (NSAIDs) in the management of patent ductus arteriosus (PDA) in preterm infants and variations in attitude in clinical practice: a flight around the world. Current medicinal chemistry 2014. link 33 van der Lugt NM, Lopriore E, Bökenkamp R, Smits-Wintjens VE, Steggerda SJ, Walther FJ. Repeated courses of ibuprofen are effective in closure of a patent ductus arteriosus. European journal of pediatrics 2012. link 34 Sarici SU, Dabak O, Erdinc K, Okutan V, Lenk MK. An unreported complication of intravenously administered ibuprofen: gastrointestinal bleeding. European review for medical and pharmacological sciences 2012. link 35 Neumann R, Schulzke SM, Bührer C. Oral ibuprofen versus intravenous ibuprofen or intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Neonatology 2012. link 36 Desandes R, Jellimann JM, Rouabah M, Haddad F, Desandes E, Boubred F et al.. Echocardiography as a guide for patent ductus arteriosus ibuprofen treatment and efficacy prediction. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2012. link 37 Bersani I, De Carolis MP, Lacerenza S, De Rosa G, Fusco FP, Cota F et al.. Is the prophylaxis of patent ductus arteriosus useful in extremely premature infants?. The Turkish journal of pediatrics 2011. link 38 Schena F, Ciarmoli E, Mosca F. Patent ductus arteriosus: wait and see?. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2011. link 39 Dani C. New therapeutic strategies for the treatment of patent ductus arteriosus in preterm infants. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2011. link 40 Ohlsson A, Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. The Cochrane database of systematic reviews 2011. link 41 Uchiyama A, Nagasawa H, Yamamoto Y, Tatebayashi K, Suzuki H, Yamada K et al.. Clinical aspects of very-low-birthweight infants showing reopening of ductus arteriosus. Pediatrics international : official journal of the Japan Pediatric Society 2011. link 42 Pees C, Walch E, Obladen M, Koehne P. Echocardiography predicts closure of patent ductus arteriosus in response to ibuprofen in infants less than 28 week gestational age. Early human development 2010. link 43 Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. The Cochrane database of systematic reviews 2010. link 44 Guimarães H, Rocha G, Tomé T, Anatolitou F, Sarafidis K, Fanos V. Non-steroid anti-inflammatory drugs in the treatment of patent ductus arteriosus in European newborns. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2009. link 45 Pourarian Sh, Pishva N, Madani A, Rastegari M. Comparison of oral ibuprofen and indomethacin on closure of patent ductus arteriosus in preterm infants. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit 2008. link 46 Cherif A, Jabnoun S, Khrouf N. Oral ibuprofen in early curative closure of patent ductus arteriosus in very premature infants. American journal of perinatology 2007. link 47 Shah SS, Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. The Cochrane database of systematic reviews 2006. link 48 Vandekerckhove K, Macrae D, Slavik Z. Nonsurgical treatment of patent arterial duct in term neonates with congenital heart disease: the role of intravenous indomethacin. Pediatric cardiology 2005. link 49 Auer M, Brezinka C, Eller P, Luze K, Schweigmann U, Schwärzler P. Prenatal diagnosis of intrauterine premature closure of the ductus arteriosus following maternal diclofenac application. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2004. link 50 Shah SS, Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. The Cochrane database of systematic reviews 2003. link 51 Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of a patent ductus arteriosus in preterm and/or low birth weight infants. The Cochrane database of systematic reviews 2003. link 52 Lago P, Bettiol T, Salvadori S, Pitassi I, Vianello A, Chiandetti L et al.. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. European journal of pediatrics 2002. link 53 Knight DB. The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. Seminars in neonatology : SN 2001. link 54 Rein AJ, Nadjari M, Elchalal U, Nir A. Contraction of the fetal ductus arteriosus induced by diclofenac. Case report. Fetal diagnosis and therapy 1999. link

Infectious endarteritis of arterial duct